CliffBio
biologic

Bimzelx

bimekizumab-bkzx

Loss of exclusivityOctober 2035projected — 12-year biologic exclusivity estimate
CompanyUCB →View the full company profile on CliffBio

Drug detail

Brand nameBimzelx
Active ingredientbimekizumab-bkzx
Strength160MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalOctober 2023
Marketing statusRx

More from UCB

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Bimzelx patent cliff — loss of exclusivity October 2035 | CliffBio